Oscient issues forecast

Oscient Pharmaceuticals Inc. of Waltham said today that it expects to record third-quarter revenues of about $15.5 million, up from $12.4 million a year ago.

That increase reflects the company's acquisition of Antara tablets, an adjunct treatment for high cholesterol; the acquisition was completed in August 2006, halfway through the third quarter of that year, Oscient said.

Oscient said it expects to record about $12.5 million in revenue from Antara and about $3 million from Factive, a treatment for acute bacterial exacerbations of chronic bronchitis and for community acquired pneumonia.

Oscient said it plans to announce full results for its third quarter late this month.
(By Chris Reidy, Globe staff)